259 related articles for article (PubMed ID: 34606520)
21. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.
Orangi S; Ojal J; Brand SP; Orlendo C; Kairu A; Aziza R; Ogero M; Agweyu A; Warimwe GM; Uyoga S; Otieno E; Ochola-Oyier LI; Agoti CN; Kasera K; Amoth P; Mwangangi M; Aman R; Ng'ang'a W; Adetifa IM; Scott JAG; Bejon P; Keeling MJ; Flasche S; Nokes DJ; Barasa E
BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35914832
[TBL] [Abstract][Full Text] [Related]
22. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia.
Lusvan ME; Debellut F; Clark A; Demberelsuren S; Otgonbayar D; Batjargal T; Purevsuren S; Groman D; Tate J; Pecenka C
Vaccine; 2019 Feb; 37(6):798-807. PubMed ID: 30639458
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission.
Orellano PW; Reynoso JI; Stahl HC; Salomon OD
Vaccine; 2016 Jan; 34(5):616-621. PubMed ID: 26724542
[TBL] [Abstract][Full Text] [Related]
24. A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine.
Kirwin E; Rafferty E; Harback K; Round J; McCabe C
Pharmacoeconomics; 2021 Sep; 39(9):1059-1073. PubMed ID: 34138458
[TBL] [Abstract][Full Text] [Related]
25. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
Bar-Zeev N; Tate JE; Pecenka C; Chikafa J; Mvula H; Wachepa R; Mwansambo C; Mhango T; Chirwa G; Crampin AC; Parashar UD; Costello A; Heyderman RS; French N; Atherly D; Cunliffe NA;
Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S220-8. PubMed ID: 27059360
[TBL] [Abstract][Full Text] [Related]
27. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis.
Stevenson M; Metry A; Messenger M
Health Technol Assess; 2021 Jun; 25(39):1-74. PubMed ID: 34142943
[TBL] [Abstract][Full Text] [Related]
28. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India.
Gupta M; Prinja S; Kumar R; Kaur M
Health Policy Plan; 2013 Jan; 28(1):51-61. PubMed ID: 22407018
[TBL] [Abstract][Full Text] [Related]
30. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
Hogan AB; Winskill P; Ghani AC
PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
32. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
Li X; Mukandavire C; Cucunubá ZM; Echeverria Londono S; Abbas K; Clapham HE; Jit M; Johnson HL; Papadopoulos T; Vynnycky E; Brisson M; Carter ED; Clark A; de Villiers MJ; Eilertson K; Ferrari MJ; Gamkrelidze I; Gaythorpe KAM; Grassly NC; Hallett TB; Hinsley W; Jackson ML; Jean K; Karachaliou A; Klepac P; Lessler J; Li X; Moore SM; Nayagam S; Nguyen DM; Razavi H; Razavi-Shearer D; Resch S; Sanderson C; Sweet S; Sy S; Tam Y; Tanvir H; Tran QM; Trotter CL; Truelove S; van Zandvoort K; Verguet S; Walker N; Winter A; Woodruff K; Ferguson NM; Garske T;
Lancet; 2021 Jan; 397(10272):398-408. PubMed ID: 33516338
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study.
Reddy KP; Shebl FM; Foote JHA; Harling G; Scott JA; Panella C; Fitzmaurice KP; Flanagan C; Hyle EP; Neilan AM; Mohareb AM; Bekker LG; Lessells RJ; Ciaranello AL; Wood R; Losina E; Freedberg KA; Kazemian P; Siedner MJ
Lancet Glob Health; 2021 Feb; 9(2):e120-e129. PubMed ID: 33188729
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
35. Health impact and cost-effectiveness of expanding routine immunization coverage in India through Intensified Mission Indradhanush.
Clarke-Deelder E; Suharlim C; Chatterjee S; Portnoy A; Brenzel L; Ray A; Cohen JL; Menzies NA; Resch SC
Health Policy Plan; 2024 Jun; 39(6):583-592. PubMed ID: 38590052
[TBL] [Abstract][Full Text] [Related]
36. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
38. Measures implemented in the school setting to contain the COVID-19 pandemic.
Krishnaratne S; Littlecott H; Sell K; Burns J; Rabe JE; Stratil JM; Litwin T; Kreutz C; Coenen M; Geffert K; Boger AH; Movsisyan A; Kratzer S; Klinger C; Wabnitz K; Strahwald B; Verboom B; Rehfuess E; Biallas RL; Jung-Sievers C; Voss S; Pfadenhauer LM
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD015029. PubMed ID: 35037252
[TBL] [Abstract][Full Text] [Related]
39. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
40. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
